|
HALO | Halozyme Therapeutics, Inc. |
|
|
HALO | Halozyme Therapeutics, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.05 |
| Leverage | 82.37% |
| Market Cap | $ 7.4B |
| PE | 16.76 |
| Dividend Yield | 0.00% |
| Profit | $ 441.1m |
| Margin | 42.73% |
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.